Cargando…

Bleeding Risk and Mortality of Edoxaban: A Pooled Meta-Analysis of Randomized Controlled Trials

OBJECTIVE(S): Edoxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unexplored. METHODS: Medline, Embase and Web of Science were searched to March 8, 2014 for prospective, randomized controlled tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shuang, Liu, Baoxin, Xu, Dachun, Xu, Yawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988190/ https://www.ncbi.nlm.nih.gov/pubmed/24736694 http://dx.doi.org/10.1371/journal.pone.0095354

Ejemplares similares

Edoxaban: Minor bleeding: case report
Publicado: (2022)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

High incidence of major bleeding with off-label use of edoxaban
por: Fukui, Rika, et al.
Publicado: (2021)

Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
por: Mikami, Ryusei, et al.
Publicado: (2023)

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban
por: Takase, Tomoki, et al.
Publicado: (2019)

Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban
por: Han, Ji Min, et al.
Publicado: (2023)

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study
por: Ikushima, Ippei, et al.
Publicado: (2020)

Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
por: Wang, Wei, et al.
Publicado: (2020)

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials
por: Tai, Chenhui, et al.
Publicado: (2017)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Angiotensin II Receptor Blockers Improve Peripheral Endothelial Function: A Meta-Analysis of Randomized Controlled Trials
por: Li, Shuang, et al.
Publicado: (2014)

Prophylactic antibiotics on patients with cirrhosis and upper gastrointestinal bleeding: A meta-analysis
por: Gao, Yanying, et al.
Publicado: (2022)

Risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Hurst, Katherine V, et al.
Publicado: (2016)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
por: Lu, Genmin, et al.
Publicado: (2018)

Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Tellor, Katie B, et al.
Publicado: (2016)

Managing patients taking edoxaban in dentistry
por: Curto, Adrian, et al.
Publicado: (2017)

Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub‐Analysis of the ELDERCARE‐AF Trial
por: Mikami, Takeshi, et al.
Publicado: (2022)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
por: Nitta, Kenichi, et al.
Publicado: (2016)

Superior mesenteric vein thrombosis treated with edoxaban
por: Hashizume, Yutaka, et al.
Publicado: (2017)

Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
por: Sokol, Juraj, et al.
Publicado: (2020)

Use of Edoxaban for the Treatment of Heparin-Induced Thrombocytopenia
por: Kanamoto, Ryo, et al.
Publicado: (2020)

Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban
por: Rashid, Md Abdur, et al.
Publicado: (2022)

Life-threatening pericardial bleed complicating atrial fibrillation ablation associated with edoxaban therapy successfully managed with prothrombin complex concentrate
por: Choudhury, Moinuddin, et al.
Publicado: (2019)

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
por: Colonna, Paolo, et al.
Publicado: (2018)

Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials
por: Mahmoodi, Bakhtawar K., et al.
Publicado: (2021)

Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
por: Xiao, Bingkun, et al.
Publicado: (2018)

Enhancement in efferocytosis of oxidized low-density lipoprotein-induced apoptotic RAW264.7 cells through Sirt1-mediated autophagy
por: LIU, BAOXIN, et al.
Publicado: (2014)

Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
por: Douxfils, Jonathan, et al.
Publicado: (2014)

Influenza or Meningococcal Immunization During Pregnancy and Mortality in Women and Infants: A Pooled Analysis of Randomized Controlled Trials
por: Clark, Dayna R., et al.
Publicado: (2020)

Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF/VTE study
por: Colonna, Paolo, et al.
Publicado: (2020)

Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial
por: Akashi, Shintaro, et al.
Publicado: (2022)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE study
por: Scheres, LJJ, et al.
Publicado: (2018)

Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study
por: Abe, Ichitaro, et al.
Publicado: (2021)

Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wang, Jinjin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_00hh17u22mq6uni9g3h47sjfrb